期刊名称：CYTOJOURNAL
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
CytoJournal is an Open Access, peer-reviewed, PubMed Indexed, predominantly online journal that publishes cutting edge research articles and information related to all aspects of diagnostic cytopathology, including complementary topics such as molecular cytopathology.
Abstracting and Indexing information
The journal is indexed with Caspur, DOAJ, EBSCO Publishing's Electronic Databases, Excerpta Medica / EMBASE, Expanded Academic ASAP, Genamics JournalSeek, Google Scholar, Health & Wellness Research Center, Health Reference Center Academic, Hinari, Index Copernicus, Journal Citation Reports, OpenJGate, PrimoCentral, ProQuest, PubMed, Pubmed Central, Science Citation Index Expanded, Scimago Journal Ranking, SCOLOAR, SCOPUS, SIIC databases, Summon by Serial Solutions, Ulrich's International Periodical Directory, Web of Science
CytoJournal is supported by an elaborate Editorial Board which includes experts with variety of expertise and interests from diverse regions of the globe.
Cytopathology is a well-established diagnostic sub-specialty of pathology. Instead of using surgically removed tissue to arrive at a diagnosis it attempts to identify diagnostic and prognostic information from dispersed cells obtained by non-invasive or minimally invasive techniques. An example, and its greatest success story thus far, is the role it has played in the battle against cervical cancer. Indeed, the Pap smear introduced by George Papanicolaou has contributed immensely to the early diagnosis and significantly decreased mortality of cervical cancer.
Free flow of scientific information is crucial for the advancement of disease diagnosis and management in the developed and developing world. CytoJournal as an Open Access, online journal, quality controlled through traditional peer review processes and the first of its kind in the field of cytopathology. It should positively influence the advancement of the scientific community around the world.
Instructions to Authors
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf (except in rare cases by the editorial office at the request of the submitting author in rare cases for unforeseen reasons after due documentation). The submitting author takes responsibility for the article during submission and peer review.
To facilitate rapid publication and to minimize administrative costs, CytoJournal accepts only online submission. The submission process is compatible with version 5.5 or later of Internet Explorer and Netscape Navigator, and with most other modern web browsers. It can be used from PC, Mac, or Unix platforms.
Files can be submitted as a batch, or one by one. The submission process can be interrupted at any time - when users return to the site, they can carry on where they left off.
See below for examples of acceptable word processor and graphics file formats. Additional files of any type, such as movies, animations, or original data files, can also be submitted as part of the publication.
Please refer to Submission checklist
Please check the following points before proceeding.
1. Manuscript files
Do you have all the files for the manuscript in an acceptable format?
Main manuscript
Manuscript is split in to the following parts (steps):
a. First page file [First page template (Research)] [First page template (Case Report)]
· Use text/rtf/doc/pdf file (Max size 100 KB). This should include the following:
· The title of the article. The title should be catchy and intuitive about the article topic. It should preferably include the study design.
· Author details: The full names, institutional addresses, and e-mail addresses for all authors must be included on the title page.
· The details of corresponding author should include- e-mail address, mailing address, phone & fax numbers (country & area code).
· Other statements- Conflict of Interest statement, authorship statement, Acknowledgement(s) (if any) (see first page templates).
(Any other details unrelated to the actual article and may have author / institution identification)
b. Article file [Manuscript template (Research)] [Manuscript template (Case Report)]
· Use text/rtf/doc/pdf file (Max size 400 KB) Should contain the Title and text from abstract onwards.
No information which can reveal contributors' identity should be included in this file (e.g. acknowledgement).
The automatic online review system sends only ‘article file’ to the reviewers without any author details.
c. Figure/video files (must be separate files and should NOT be embedded in the main manuscript).
Each figure should be a separate file. Sketches, different diagrams including bar diagrams and pie charts, algorithms, and flow charts should be submitted as figures. DONOT submit tables with columns and rows as figures.
· IMAGES: Formats: PNG, TIFF (for photographs and screen dumps), JPEG. · FIGURES: Formats PPT · VIDEOS: Formats mpg, mpeg, mp4, wmv
CME questions: Some type of articles (research articles, methodology articles, case reports, quiz cases, review articles, and Cytojournal monograph articles) require at least 3 multiple choice questions for CME. For general guidelines, please use the following manual available free online:
Constructing Written Test Questions For the Basic and Clinical Sciences http://www.nbme.org/PDF/ItemWriting_2003/2003IWGwhole.pdf
2. Suggest reviewers: You will have opportunity to suggest reviewers at the end of the manuscript submission.
Please suggest particularly qualified reviewers who have had experience in the subject of the submitted manuscript, but who are not affiliated with the same institutes as the contributor/s. CytoJournal peer-review system may or may not include the suggested peer-reviewer depending on reviewer availability and editor decision. The reviewer may be included in the core peer-reviewer list for future other manuscripts on similar topics.
Please keep their names and e-mail addresses ready to copy-paste.
3. Article Publication Charge (APC)
Journal does not charge for submission or publication fee on article.
4. Are you one of the authors of this article?
If not, you cannot submit the article on behalf of the authors. The submitting author takes responsibility for the article during submission and peer review.
5. Conditions of submission and CytoJournal Copyright and License Agreement
Do you confirm that all the authors of the manuscript have read and agreed to its content, that readily reproducible materials described in the manuscript will be freely available to any scientist wishing to use them for non-commercial purposes , and that you have ethical approval for any human or animal experimentation (for more information see our Instructions for Authors)? Do you confirm that the manuscript is original, has not already been published in a journal and is not currently under consideration by another journal? To read the terms of the CytoJournal Copyright and License Agreement, please click this link.
Peer review policies
Click here to read
Publication
Once an article is accepted, it is published in CytoJournal. The article will be published in both fully browseable web form (HTML), and as a formatted PDF. Tthe HTML of the article will then be available through CytoJournal and PubMed Central, and will also be included in PubMed.
Article Publication Charge (APC)
CytoJournal levies an article publication charge (APC) for every accepted article, to cover the costs incurred for open access publication. Currently the article-processing charge is US$1500.
APC was waived during 2008 and 2009. The generosity of readers and authors to support this ‘open access charter’ of CytoJournal to allow dissemination of scientific peer-reviewed cytopathology literature around the globe is highly appreciated.
APC is waived for following:
1. Cytopathology Foundation (CF) members. Please click here to become CF member (US $ 50 / year OR US $ 1000 for life)
2. All members of organizations/societies/and other entities as ‘CytoJ OA Stewards-Plus’. Please click here to check if your society-organization is ‘CytoJ OA Stewards-Plus’
APC is subsidized to US$ 500 for following:
All members of organizations/societies/and other entities identified as and included in the list of ‘CytoJ OA Stewards’, get partial but significant waiver ($500 instead of $1500). Please click here to check if your society-organization is ‘CytoJ OA Stewards’ without any financial obligation to it.
APC may also be waived or subsidized to:
Group with reasonable proof of financial hardship to afford any of the pathways shown above.
Waivers may be granted, particularly for authors from countries / institutions with financial hardship. For further details, see more information about article publication charges
Any manuscript submitted to CytoJournal must not already have been published in another journal or be under consideration by any other journal.
Manuscripts must not have already been published in any journal or other citable form, with the exception that the journal is willing to consider peer-reviewing manuscripts that are translations of articles originally published in another language. In this case, the consent of the journal in which the article was originally published must be obtained and the fact that the article has already been published must be made clear on submission and stated in the abstract.
Manuscripts that are derived from papers presented at conferences may be submitted unless they have already been published as part of the conference proceedings in a peer reviewed journal. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party. Authors who publish in CytoJournal retain copyright to their work (more information http://creativecommons.org/licenses/by/2.0/ ); however. They agree to share it in public domain for non-commercial purposes. The royalties earned from commercial use may be shared through www.copyright.com. Correspondence concerning articles published in CytoJournal is encouraged.
Guideline for duplicate publication as flowchart is at COPE:
http://www.publicationethics.org.uk/flow-charts/cope-flowcharts-optimal.pdf/view
Submission of a manuscript to CytoJournal implies that all authors have read and agreed to its content, and that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee and Institutional Review Board (IRB) or its counterpart as indicated by local policies, standards, and laws.
Research carried out on humans must be in compliance with the Helsinki Declaration http://www.wma.net/e/policy/b3.htm , and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Informed consent must also be documented. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within an ethical framework, e.g. if the severity of the experimental procedure is not justified by the value of the knowledge gained.
Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in parentheses in the Methods section.
Authors of CytoJournal articles complete a declaration of competing interests, which is provided as a separate section of the manuscript as part of first page file. This information is included in the finally published version, if the manuscript is accepted for publication.
Competing interests
A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.
Authors are required to complete a declaration of competing interests. The information on competing interests will be included in the published articles.
When completing your declaration, please consider the following questions:
Financial competing interests
· In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
· Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
· Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
· Do you have any other financial competing interests? If so, please specify.
Non-financial competing interests
Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.
If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss it with the editorial office.
In the absence of competing interests, the declaration may read 'The author(s) declare that they do not have competing interests'. Much has been written about competing interests (or conflict of interest, as other journals call it) within scientific research, but the following articles provide some background:
R Smith: Beyond conflict of interest. BMJ 1998, 317 :291-292
R Smith: Making progress with competing interests. BMJ 2002, 325 :1375-1376
CD DeAngelis, PB Fontanarosa, A Flanagin: Reporting financial conflicts of interest and relationships between investigators and research sponsors. JAMA 2001, 286 :89-9
K Morin, H Rakatansky, FA Riddick Jr, LJ Morse, JM O'Bannon 3rd, MS Goldrich, P Ray, M Weiss, RM Sade, MA Spillman: Managing conflicts of interest in the conduct of clinical trials. JAMA 2002, 287 :78-84
For all articles that include patients identifiable information or clinical photographs relating to individual patients, written and signed consent from each patient to publish must also be mailed or faxed to the editorial staff. The manuscript should also include a statement to this effect in the Acknowledgements section, as follows: "Written consent for publication was obtained from the patient or their relative."
CytoJournal supports initiatives to improve the performance and reporting of clinical trials, part of which includes prospective registering and numbering of trials. While there are initiatives to ensure that all clinical trials are registered (most notably the recent statement from the International Committee of Medical Journal Editors - see http://www.icmje.org/clin_trialup.htm ), we are focusing on controlled trials of healthcare interventions, for now. Authors of protocols or reports of controlled trials of health care interventions must register their trial prior to submission in a suitable publicly accessible registry. The trial registers that currently meet all of the ICMJE guidelines can be found at http://www.icmje.org/faq.pdf .
The trial registration number should be included as the last line of the abstract of the manuscript.
CytoJournal also supports initiatives aimed at improving the reporting of biomedical research. Checklists have been developed for randomized controlled trials (CONSORT http://www.consort-statement.org/index.aspx?o=1065 ), systematic reviews (QUOROM http://www.consort-statement.org/index.aspx?o=1065 ), meta-analyses of observational studies (MOOSE http://www.consort-statement.org/index.aspx?o=1065 ), diagnostic accuracy studies (STARD http://www.consort-statement.org/index.aspx?o=1065 ) and qualitative studies (RATS (see at end). Authors are requested to make use of these when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these studies. For authors of systematic reviews, a supplementary file, linked from the Methods section, should reproduce all details concerning the search strategy. For an example of how a search strategy should be presented, see the Cochrane Reviewers' Handbook http://www.cochrane.dk/cochrane/..../r_studies_and_organizing_search_results.htm .
Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Good Publication Practice guidelines for pharmaceutical companies http://www.gpp-guidelines.org/ , which are designed to ensure that publications are produced in a responsible and ethical manner. The guidelines also apply to any companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations and communications companies.
The involvement of medical writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged, along with their source of funding, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications http://www.emwa.org/Mum/EMWAguidelines.pdf . If medical writers are not listed among the authors, it is important that their role be acknowledged explicitly. We suggest wording such as 'We thank Jane Doe who provided medical writing services on behalf of XYZ Pharmaceuticals Ltd.'
Submission of a manuscript to CytoJournal implies that readily reproducible materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and atomic coordinates should be deposited in an appropriate database in time for the accession number to be included in the published article. In computational studies where the sequence information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published as an additional file with the article.
Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.
Nucleotide sequences
Nucleotide sequences can be deposited with the
DNA Data Bank of Japan (DDBJ)
http://www.ddbj.nig.ac.jp/ ,
European Molecular Biology Laboratory (EMBL/EBI) Nucleotide Sequence Database
http://www.ebi.ac.uk/ , or
GenBank (National Center for Biotechnology Information)
http://www.ncbi.nlm.nih.gov/ .
Protein sequences
Protein sequences can be deposited with SwissProt http://pubchem.ncbi.nlm.nih.gov/ or the Protein Information Resource (PIR) http://pir.georgetown.edu/ .
Structures
Protein structures can be deposited with one of the members of the Worldwide Protein Data Bank http://www.wwpdb.org/ . Nucleic Acids structures can be deposited with the Nucleic Acid Database http://ndbserver.rutgers.edu/ at Rutgers. Crystal structures of organic compounds can be deposited with the Cambridge Crystallographic Data Centre http://www.ccdc.cam.ac.uk/products/csd/deposit/ .
Chemical structures and assays
Structures of chemical substances can be deposited with PubChem Substance http://pubchem.ncbi.nlm.nih.gov/ . Bioactivity screens of chemical substances can be deposited with PubChem BioAssay http://www.ncbi.nlm.nih.gov/sites/entrez?db=pcassay .
Microarray data
Where appropriate, authors should adhere to the standards proposed by the Microarray Gene Expression Data Society http://www.mged.org/ and must deposit microarray data in one of the public repositories, such as ArrayExpress http://www.mged.org/ , Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/projects/geo/ or the Center for Information Biology Gene Expression Database (CIBEX) http://cibex.nig.ac.jp/ .
Computional modeling
We encourage authors to prepare models of biochemical reaction networks using the Systems Biology Markup Language http://sbml.org/index.php/Main_Page and to deposit the model with the BioModels database http://www.ebi.ac.uk/biomodels/ , as well as submitting it as an additional file with the manuscript.
Plasmids
We encourage authors to deposit copies of their plasmids as DNA or bacterial stocks with Addgene http://www.addgene.org/pgvec1 , a non-profit repository, or PlasmID http://plasmid.med.harvard.edu/PLASMID/ , the Plasmid Information Database at Harvard.
CytoJournal endorses the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions http://www.wame.org/resources/policies
File formats
The following word processor file formats are acceptable for the main manuscript document:
· Microsoft Word (version 2 and above)
· WordPerfect (version 5 and above)
· Rich text format (RTF)
· Portable document format (PDF)
Users of other word processing packages should save or convert their files to RTF before uploading. Many free tools are available which ease this process.
Note that figures must be submitted as separate image files, not as part of the submitted DOC/ PDF file. However, tables are part of the manuscript file. DONOT submit tables with columns and rows as figures. Sketches, different diagrams including bar diagrams and pie charts, algorithms, and flow charts should be submitted as figures.
Article types
CytoJournal considers the following types of articles:
· Research article - reports of data from original research.
· Methodology articles - present a new experimental method, test or procedure. The method described may either be completely new, or may offer a better version of an existing method. The article must describe a demonstrable advance on what is currently available.
· Case reports - reports of clinical cases that can be educational by discussing a diagnostic dilemma and reporting relatively rare phenomenon or clinical association.
· Quiz case- Presenting a clinical case to communicate teaching point(s) by presenting it in a quiz format to generate an inquisitive interest for educational progress.
· Review - comprehensive, authoritative descriptions of any subject within the scope of CytoJournal; these articles are usually written by opinion leaders that have been invited by the Editorial Board.
· CytoJournal Monograph related review series - comprehensive, authoritative descriptions of any subject within the scope of CytoJournal; these reviews are usually written by opinion leaders that have been invited by the CytoJournal Monograph & Atlas (CMAS) committee and peer-reviewed under leadership of CytoJournal Monograph & Atlas (CMAS) Editorial Board. The peer-review process for these series is not double blind.
· Editorials - short, focused and opinionated articles on any subject within the scope of CytoJournal; these articles are usually related to a contemporary issue, such as recent research findings, and are often written by opinion leaders invited by the Editorial Board.
· Book reviews - short summaries of the strengths and weaknesses of a book; they should evaluate its overall usefulness to the intended audience.
· Letters to the editor - short, focused and opinionated brief letter on any subject within the scope of CytoJournal; these articles are usually related to a contemporary issue, written by readers.
Please read the descriptions of each of the article types, choose which is appropriate for your article and structure it accordingly.
Some type of articles (research articles, methodology articles, case reports, quiz cases, review articles, and Cytojournal monograph articles) require at least 3 multiple choice questions for CME. For general guidelines, please use the following manual available free online:
Constructing Written Test Questions For the Basic and Clinical Sciences http://www.nbme.org/PDF/ItemWriting_2003/2003IWGwhole.pdf
If in doubt, your manuscript may be classified as Research, the editorial process will reclassify it as needed.
Manuscript preparation
You may download different templates First page template (Research), Article file template (Case Report), Article file template (Research) . For instructions how to use the templates, see below.
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should be provided, in square brackets and include the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116].
The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (DDBJ ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).
Title page
This should list the title of the article. The title should include the study design, for example:
A versus B in the treatment of C: a randomized controlled trial
X is a risk factor for Y: a case control study
The full names, institutional addresses, and e-mail addresses for all authors must be included on the title page. The corresponding author should also be indicated.
Abstract
The abstract of the manuscript should not exceed 350 words and must be structured into separate sections: Background, the context and purpose of the study; Methods, how the study was performed and statistical tests used; Results, the main findings; Conclusions, brief summary and potential implications.
Please minimize the use of abbreviations and do not cite references in the abstract.
Trial registration, if your research article reports the results of a controlled health care intervention, please list your trial registry, along with the unique identifying number, e.g. Trial registration: Current Controlled Trials ISRCTN73824458. Please note that there should be no space between the letters and numbers of your trial registration number.
Background
The background section should be written from the standpoint of researchers without specialist knowledge in that area and must clearly state - and, if helpful, illustrate - the background to the research and its aims. Reports of clinical research should, where appropriate, include a summary of a search of the literature to indicate why this study was necessary and what it aimed to contribute to the field. The section should end with a very brief statement of what is being reported in the article.
Methods
This should include the design of the study, the setting, the type of participants or materials involved, a clear description of all interventions and comparisons, and the type of analysis used, including a power calculation if appropriate.
Results and Discussion
The Results and Discussion may be combined into a single section or presented separately. Results of statistical analysis should include, where appropriate, relative and absolute risks or risk reductions, and confidence intervals. The results and discussion sections may also be broken into subsections with short, informative headings.
Conclusions
This should state clearly the main conclusions of the research and give a clear explanation of their importance and relevance. Summary illustrations may be included.
List of abbreviations used in the article (in alphabetic order)
If abbreviations are used in the text either they should be defined in the text where first used, or a list of abbreviations can be provided, which should precede the competing interests and authors' contributions.
Competing interests
A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment were they to become public after the publication of the manuscript.
Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed at the end of published articles. Where an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.
When completing your declaration, please consider the following questions:
Financial competing interests
· In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including the article-processing charge)? If so, please specify.
· Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? If so, please specify.
· Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
· Do you have any other financial competing interests? If so, please specify.
Non-financial competing interests
Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify.
If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss it with the editorial office.
Editorial Board
Editor-Emeritus
Barbara F. Atkinson, MD
Exec Vice Chancellor, Kansas University Med Center, Kansas City, KS, USA
Editors-in-Chief
Richard M. DeMay, MD
University of Chicago, Chicago, IL, USA
Martha B. Pitman, MD
Harvard Medical School, Boston, MA USA
Vinod B. Shidham, MD, FRCPath, FIAC
Wayne State University School of Medicine & Detroit Medical Center, Detroit, MI, USA
CytoJ Monograph Committee Co-chairs
Zubair Baloch, MD, PhD
University of Pennsylvania Medical Center, Philadelphia, PA, USA
Shikha Bose, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
CytoJ Monograph coeditors-in-chief
R. Marshal Austin, MD, PhD
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Ruth Katz, MD
M.D. Anderson Cancer Center, Houston, TX, USA
David C. Wilbur, MD
Harvard Medical School, Boston, MA USA
Cytotechnology panel
J amie L. Covell BS, CT(ASCP)
University of Virginia Health Sciences Center, Charlottesville, VA, USA
Inderpreet Dh illon, MS, CT (ASCP)
Detroit Medical Cente r, Detroit, MI, USA
Gary W. Gill,
Indianapolis, IN, USA
Kalyani Naik, MS, SCT(ASCP)
University of Michigan Hospital, Ann Arbor, MI, USA
Consultant editors
John N. Eble, MD, MBA
Editor-in-chief, Modern Pathology,
Indiana University School of Medicine, Indianapolis, IN, USA.
Stacey E. Mills, MD
Editor-in-chief, American Journal of Surgical Pathology
University of Virginia Health Science Center, Charlottesville, VA, USA
Mark R. Wick, MD
Editor-in-chief, American Journal of Clinical Pathology
University of Virginia Health Science Center, Charlottesville, VA, USA
‘Best in CytoJ’ Award Committee Chair
Michael B. Cohen, MD
Richard G. Lynch Chair of Experimental Pathology
The University of Iowa, IA, US
Founding Editor
Vinod B. Shidham, MD, FRCPath, FIAC
Wayne State University School of Medicine, De troit.
Executive-Editor
Vinod B. Shidham, MD, FRCPath, FIAC
Wayne State Univ School of Medicine, Detroit, M I, USA
Associate editors (Ad Hoc)
Lester Layfield, MD
University of Utah School of Medicine, Salt Lake City, UT, USA
Eva M. Wojcik, MD
Loyola University Medical Center, Chicago, IL, USA
Associate editors (Rotating)
Shikha Bose, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
David C. Chhieng, MD, MBA, MSHI
Yale University, New Haven, CT, USA
Mamatha Chivukula, MD
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Isam A. Eltoum, MD, MBA
University of Alabama at Birmingham, Birmingham, AL, USA
Rana S. Hoda, MD, FIAC
Weill Cornell Medical College, New York, NY, USA
Nirag Jhala, MD, MIAC
University of Pennsylvania Medical Center, Philadelphia, PA, USA
Gladwyn Leiman, MBBCh FIAC FRCPath
University of Vermont, Burlington, VT, USA
Sanjay Logani, MD, MIAC
InCyte Pathology, Spokane Valley, WA, USA
Sonya Naryshkin, MD, FIAC
Mercy Health System, Janesville, WI, USA
Liron Pantanowitz, MD
University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Husain Saleh, MD, FIAC, MBA
Wayne Sate University School of Medicine, Detroit, MI, USA
Momin T. Siddiqui, MD, FIAC
Emory University, Atlanta, GA, USA
Lourdes R. Ylagan, MD, FIAC
Roswell Park Cancer Institute, Buffalo, NY, USA
Editorial Board Members
R. Marshall Austin, MD, PhD (USA)
Zubair Baloch, MD, PhD (USA)
George Birdsong, MD (USA)
Thomas A. Bonfiglio, MD (USA)
Shikha Bose, MD (USA)
David C. Chhieng, MD, MBA, MSHI (USA)
Mamatha Chivukula, MD (USA)
Douglas P Clark, MD (USA)
Michael B. Cohen, MD (USA)
Diane D Davey, MD (USA)
Richard M DeMay, MD (USA)
Hormoz Ehya, MD (USA)
Isam A. Eltoum, MD, MBA (USA)
James England, MD, PhD (USA)
Yener S Erozan, MD (USA)
Prabodh Gupta, MBBS,MD, FIAC (USA)
Amanda Herbert, MBBS, FRCPath (UK)
Rana S. Hoda, MD (USA)
Nirag Jhala, MD, MIAC (USA)
Kusum Kapila, MD, FIAC, FRCPath (Kuwait)
Ruth Katz, MD (USA)
Sudha R Kini, MD (USA)
Savitri Krishnamurthy, MD (USA)
Lester Layfield, MD (USA)
Gladwyn Leiman, MBBCh FIAC FRCPath (USA)
Virginia LiVolsi, MD (USA)
Britt-Marie Ljung, MD (USA)
Sanjay Logani, MD, FCAP, FASCP, MIAC (USA)
Shahla Masood, MD (USA)
Alexander Meisels, MD, FIAC (Canada)
Dina R Mody, MD (USA)
Sonya Naryshkin, MD, FIAC (USA)
Norimichi Nemoto, MD (Japan)
Santo V Nicosia (USA)
Svante R Orell, MD, FIAC (Australia)
Martha B Pitman, MD ((USA)
Liron Pantanowitz, MD (USA)
David L Rimm, MD, PhD (USA)
Husain Saleh, MD, FIAC, MBA (USA)
Volker Schneider, MD, FIAC (Germany)
Suzanne Selvaggi, MD (USA)
Mark E Sherman, MD (USA)
Vinod B Shidham, MD, FRCPath, FIAC (USA)
Mary K Sidawy, MD (USA)
Momin T. Siddiqui, MD, FIAC (USA)
Jan F Silverman, MD (USA)
Mark H Stoler, MD (USA)
Rosemary Tambouret, MD (USA)
Kusum Verma, MBBS, MD, MIAC (India)
Philippe Vielh (France)
David C Wilbur, MD (USA)
Lourdes R. Ylagan, MD, FIAC (USA)
| 
